Senior Vice President, Operations and Chief Commercial Officer · Kiniksa Pharmaceuticals International, plc (KNSA)

MBChB. Qasim Rizvi

A named executive officer of Kiniksa Pharmaceuticals International in every fiscal year CompBrief holds from FY2019 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$2,252,530

Salary $431,970

FY2019: $1,503,573

3rd of 3 named executive officers at Kiniksa Pharmaceuticals International by FY2020 total.

3 named officers on file for Kiniksa Pharmaceuticals International, FY2020

MBChB. Qasim Rizvi’s pay file — $29

  • 2 fiscal years of pay, line by line
  • KNSA’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Kiniksa Pharmaceuticals International’s whole pay program stands against its peers

  • Kiniksa Pharmaceuticals International’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KNSA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2021 (DEF 14A).

Free

Get MBChB. Qasim Rizvi’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

MBChB. Qasim Rizvi compensation by year

Kiniksa Pharmaceuticals International Summary Compensation Table · all 2 fiscal years held
In US dollars, as Kiniksa Pharmaceuticals International reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020
Salary$392,700$431,970
Stock awards$95,088—
Option awards$880,884$1,620,173
Non-equity incentive$123,701$188,987
All other$11,200$11,400
Total$1,503,573$2,252,530

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Kiniksa Pharmaceuticals International, plc DEF 14A filed April 28, 2021, accession 0001104659-21-056540, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Kiniksa Pharmaceuticals International, plc filed document, accession 0001104659-21-056540. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2021.

$1.5M
$2.3M
FY19
FY20
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
PSU5,030$88,880—
Option31,249—$23.89
Option18,562—$17.92
Option27,499—$8.83
Option22,500—$10.61
Option75,000—$15.52
Option75,000—$15.50

Per the Outstanding Equity Awards at Fiscal Year-End table in Kiniksa Pharmaceuticals International, plc's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Kiniksa Pharmaceuticals International’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Sanj PatelChief Executive Officer and Chairman of the Board$5,313,564
Thomas BeethamExecutive Vice President, Corporate Development & Operations, Chief Legal Officer and Secretary$2,291,573
MBChB. Qasim Rizvi · this pageSenior Vice President, Operations and Chief Commercial Officer$2,252,530

The full Kiniksa Pharmaceuticals International compensation record

free company brief

This page is one person within Kiniksa Pharmaceuticals International's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Kiniksa Pharmaceuticals International proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Kiniksa Pharmaceuticals International's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

MBChB. Qasim Rizvi's compensation dossier · One-time report. No refunds.